Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Aura Biosciences reports positive clinical data on its eye cancer treatment therapy

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type of eye cancer.

Aura is a portfolio company of Arix Bioscience Plc (LSE: ARIX), a global health care and life sciences company.

De los Pinos says the company is privately held, however, a public offering would be considered towards the end of next year.

 
Meet Anglo Asian Mining PLC, Jersey Oil and Gas PLC, Europa Oil & Gas (Holdings) Plc, ANGLE plc and Eurasia Mining plc at our event, Dublin , 22 November 2018. Register here »
View full ARIX profile View Profile

Arix Bioscience Plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use